Description

Ativan 1 mg (Lorazepam) Tablets

Ativan 1 mg is an intermediate-acting oral benzodiazepine formulation containing lorazepam. It functions by binding allosterically to $\text{GABA}_A$ receptor complexes in the central nervous system, potentiating the inhibitory activity of gamma-aminobutyric acid ($\text{GABA}$). This increases chloride ion influx, producing membrane hyperpolarization that yields anxiolytic, sedative-hypnotic, muscle-relaxant, and anticonvulsant effects.

Product Overview

Primary Indications

Ativan 1 mg is prescribed under direct medical supervision for:

• Management of Anxiety Disorders: Short-term relief of severe symptoms of generalized anxiety disorder (GAD) or acute anxiety associated with depressive symptoms.

• Insomnia Due to Severe Anxiety/Stress: Short-term management of sleep-onset insomnia secondary to acute situational anxiety or transient psychological stress.

• Preoperative / Pre-Procedural Sedation: Premedication to alleviate acute anticipatory apprehension and produce light anterograde amnesia prior to minor surgical or diagnostic procedures.

• Adjunctive Therapy for Seizure Management: Oral maintenance or adjunct therapy in specific seizure regimens under continuous neurological monitoring.

Key Information & Precautions

• Dosage & Titration: 1 mg serves as a common initial therapeutic dose for adults with moderate to severe anxiety (often divided into 2 to 3 doses daily). Geriatric or debilitated patients typically initiate therapy at 0.5 mg to reduce the risk of ataxia and over-sedation.

• Metabolic Advantage: Unlike many other benzodiazepines (such as diazepam or alprazolam), lorazepam does not rely on hepatic cytochrome P450 oxidation; it undergoes direct phase-II glucuronidation. Consequently, its clearance is less impacted by age-related hepatic decline or CYP-mediated drug interactions, though caution is still required in severe hepatic impairment.

• Abuse, Misuse, and Addiction Risk: Lorazepam carries a boxed warning regarding physical dependence, psychological tolerance, and substance misuse. Therapy should be restricted to the lowest effective dose for the shortest duration (typically not exceeding 2 to 4 weeks).

• Severe Withdrawal Reactions: Abrupt cessation following continuous therapy can trigger life-threatening withdrawal symptoms, including status epilepticus, delirium, severe rebound anxiety, tremors, and dysphoria. Discontinuation mandates a gradual, medically supervised tapering protocol.

• Boxed Warning — Concomitant CNS Depressants: Co-administration with opioids, alcohol, or other sedative-hypnotics markedly increases the risk of profound sedation, respiratory arrest, coma, and fatal overdose.

• Cognitive & Psychomotor Impairment: Induces drowsiness, slowed reflexes, and impaired motor coordination. Patients must be cautioned against driving, operating heavy machinery, or performing hazardous tasks until individual tolerance is established.